BioSpace News Archive

Tampa General Hospital has opened a new 10,000-square-foot diagnostic center, located at 16521 U.S. 301 in Wimauma, that features an urgent care clinic, a primary care practice, diagnostic imaging and a laboratory..

Globe Life Inc. will release Third Quarter 2019 earnings after the market closes on Wednesday, Oct. 23 2019.

The market will accelerate at a CAGR of over 5% between 2019-2023

Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a conditional marketing authorization for V920 Ebola Zaire vaccine If affirmed by the European Commission, the vaccine will be authorized under the brand name ERVEBO® and indicated for active immunization of individuals 18 years of age or older to protect against Ebola Virus Disease caused by Zaire Ebola virus.

Cipher Pharmaceuticals Inc. announced it has received Health Canada approval, on October 10, 2019, for TRULANCE®, a Guanylate cyclase-C agonist in the form of a once-daily tablet for the treatment of adults with irritable bowel syndrome with constipation.

DEKRA Organizational Safety and Reliability, a global leader in safety at work, has announced a permanent and ongoing collaboration with Behavioral Safety Now for the 2020 Safety In Action Conference.

Bristol-Myers Squibb Company announced the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene Notes.

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for RINVOQ™ (upadacitinib), a once-daily selective and reversible JAK inhibitor

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today in New York to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule Platform (TRiM™) platform.

Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced it has submitted supplementary chemical composition and biocompatibility data to the U.S. Food and Drug Administration (FDA) in support of the Company’s Virtis pre-market approval (PMA) application for the treatment of chronic urinary retention and symptoms of overactive bladder.